NEUROVIVE PHARMACEUTICAL AB Inactive Instrument
Company NeuroVive Pharmaceutical AB Swiss Exchange
Equities
NVP
SE0002575340
Biotechnology & Medical Research
Business Summary
Sales per Business
| SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Mitochondrial Diseases
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +341.94% |
Sales per region
| SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Sweden
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +341.94% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Ellen Donnelly
CEO | Chief Executive Officer | 50 | 21-02-02 |
Eskil Elmér
FOU | Founder | 54 | 00-01-31 |
| Director of Finance/CFO | 57 | 13-11-30 | |
Dag Nesse
CTO | Chief Tech/Sci/R&D Officer | 58 | 23-01-31 |
Magnus Hansson
CTO | Chief Tech/Sci/R&D Officer | 48 | 07-12-31 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 16-04-27 | |
David Bejker
BRD | Director/Board Member | 49 | 17-04-26 |
Eskil Elmér
FOU | Founder | 54 | 00-01-31 |
Roger Franklin
BRD | Director/Board Member | 45 | 20-05-19 |
Denise Goode
BRD | Director/Board Member | 66 | 18-04-26 |
| Director/Board Member | 64 | 17-04-26 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 1,056,299,165 | 930,212,762 ( 88.06 %) | 0 | 88.06 % |
Company contact information
Sector
| 1st Jan change | Capi. | |
|---|---|---|
| +16.42% | 122B | |
| +19.02% | 113B | |
| +2.85% | 22.66B | |
| -16.20% | 21.34B | |
| -39.57% | 16.92B | |
| -11.63% | 16.68B | |
| -16.13% | 16.61B | |
| +2.68% | 13.62B | |
| +21.16% | 11.04B |
